No Data
Tourmaline Bio, Inc. Announces Virtual Investor Day to Discuss Development of Pacibekitug on December 10, 2024
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $49
Tourmaline Bio Price Target Raised to $49 From $48 at H.C. Wainwright
Tourmaline Bio's Promising Clinical Developments and Financial Stability Underpin Buy Rating
Express News | Tourmaline Bio Inc Files for Mixed Shelf of up to $350 Mln - SEC Filing
Talaris Therapeutics GAAP EPS of -$0.78 Beats by $0.05
Trytosaveabit : Larry Fink is a terrible awful person! Sad part it’s hard to trade any ticker that he don’t have a part of! He has been on a buying spree! I’ve seen at least 25 in last 24 hours! Prolly more that he has been buying!